Progression of glucose-lowering diabetes therapy in TECOS.
M Angelyn BethelSamuel S EngelSusanna R StevensYuliya LokhnyginaJie DingRobert G JosseMichael AlvarssonIrene HramiakJennifer B GreenEric D PetersonRury R Holmannull nullPublished in: Endocrinology, diabetes & metabolism (2018)
Consistent with the trial's pragmatic design, TECOS participants underwent typical progression of diabetes medications. Sitagliptin was associated with lower HbA1c, without increased risk for severe hypoglycaemia and was associated with delayed progression to insulin when added to metformin with or without SU.